Krystal Biotech, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (24% YoY growth; $965.9M cumulative since launch) with 95% gross margin, 29.5M weighted-average basic shares outstanding, and $1.1B cash/investments at quarter-end (up from $827.8M at year-end 2025). Net income Q2 was $54.8M ($1.85 basic EPS) vs. $38.3M prior year; H1 2026 net income $110.7M ($3.76 basic EPS) vs. $74.1M prior year. FY2026 non-GAAP combined R&D and SG&A expense guidance: $175–195M. Multiple clinical readouts expected H2 2026 (KB803 4Q, KB111 interim, KB707 interim); VYJUVEK launches planned Spain/Italy before year-end.
Why this rating
Strong organic product growth (24% YoY, 95% margin) on $3.5B market cap; pipeline advancement modest relative to size; no M&A, no guidance cut; ordinary quarterly performance with steady execution.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.